Abstract
The tolerability and ultimately efficacy of ADCs are limited by 2 major issues: (1) antigen expression that is too low on tumors, resulting in insufficient toxin delivery to the tumor, especially within the confines of the clinical MTD established by linker/payload-driven off-target toxicity and (2) too much antigen expression on normal healthy tissues, resulting in on-target but off-tumor toxicity. In this chapter, we will review strategies for making antibody prodrugs that have been or could be used to selectively deliver drug to a tumor compared to normal tissues. These technologies have the potential to lower on-target, off-tumor toxicities and enable better efficacy of ADCs due to better target selection and the delivery of higher concentrations of drug to tumors.
Keywords
PROBODY is a trademark of CytomX Therapeutics, Inc. All other brands and trademarks referenced herein are the property of their respective owners.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Bross PF et al (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7(6):1490
de Claro RA et al (2012) U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 18(21):5845
Amiri-Kordestani L et al (2014) FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res 20(17):4436
Rowe JM, Lowenberg B (2013) Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood 121(24):4838
Donaghy H (2016) Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs 8(4):659
de Goeij BE, Lambert JM (2016) New developments for antibody-drug conjugate-based therapeutic approaches. Curr Opin Immunol 40:14
Saber H, Leighton JK (2015) An FDA oncology analysis of antibody-drug conjugates. Regul Toxicol Pharmacol 71(3):444
Krop IE et al (2010) Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 28(6):2698
Beck A et al (2017) Strategies and challenges for the next generation of antibody–drug conjugates. Nat Rev Drug Discov 16:315
Saleh MN et al (2000) Phase I trial of the anti-Lewis Y drug Immunoconjugate BR96-doxorubicin in patients with Lewis Y-expressing epithelial tumors. J Clin Oncol 18:2282–2292
Tijink BM et al (2006) A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res 12(20 Pt 1):6064
Annunziata CM et al (2013) Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Investig New Drugs 31(1):77
Tannock IF, Rotin D (1989) Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 49(16):4373
Zhang X et al (2010) Tumor pH and its measurement. J nuclear. Medicine 51:1167
Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4(11):891
Liberti MV, Locasale JW (2016) The Warburg effect: how does it benefit Cancer cells? Trends Biochem Sci 41(3):211
Vander Heiden MG et al (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324(5930):1029
Bhattacharya B et al (2016) The Warburg effect and drug resistance. Br J Pharmacol 173(6):970
Sarkar CA et al (2002) Rational cytokine design for increased lifetime and enhanced potency using pH-activated “histidine switching”. Nat Biotechnol 20(9):908
Chaparro-Riggers J et al (2012) Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J Biol Chem 287:11090
Igawa T et al (2010) Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol 28(11):1203
Huang L et al (2016) Preclinical evaluation of a next-generation, EGFR targeting ADC that promotes regression in KRAS or BRAF mutant tumors. Presented at American Association for Cancer Research Annual Meeting, New Orleans, Louisiana, April 16 - 20, 2016 http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=43ef76fe-c845-4b4b-8531-601f2b1c2c32&cKey=bb5dcf16-e379-432f-a72c-191183729d7b&mKey=%7b1D10D749-4B6A-4AB3-BCD4-F80FB1922267%7d
Turk B (2006) Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 5:785
Kessenbrock K et al (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141(1):52
Sevenich L, Joyce JA (2014) Pericellular proteolysis in cancer. Genes Dev 28(21):2331
Bugge TH et al (2009) Type II transmembrane serine proteases. J Biol Chem 284(35):23177
Dass K et al (2008) Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 34(2):122
Murphy G (2008) The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer 8(12):929
Olson OC, Joyce JA (2015) Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nat Rev Cancer 15(12):712
Coussens LM et al (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295(5564):2387
Appleby TC et al (2017) Biochemical characterization and structure determination of a potent, selective antibody inhibitor of human MMP9. J Biol Chem 292(16):6810–6682
Marshall DC et al (2015) Selective allosteric inhibition of MMP9 is efficacious in preclinical models of ulcerative colitis and colorectal Cancer. PLoS One 10(5):e0127063
Metz S et al (2012) Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing. Protein Eng Des Sel 25:571–580
Onuoha SC (2015) Rational design of Antirheumatic Prodrugs specific for sites of inflammation. Arthritis Rheumatol 67:2662–2672
Donaldson JM et al (2009) Design and development of masked therapeutic antibodies to limit off-target effects: application to an anti-EGFR antibodies. Cancer Biol Ther 8:2147–2152
Podust VN (2016) Extension of in vivo half-life of biologically active molecules by XTEN protein polymers. J Control Release 240:52–66
Desnoyers LR et al (2013) Tumor-specific activation of an EGFR-targeting Probody enhances therapeutic index. Sci Transl Med 5:207ra144
Polu KR, Lowman HB (2014) Probody therapeutics for targeting antibodies to diseased tissue. Expert Opin Biol Ther 14:1049–1053
Singh S et al (2016) Preclinical development of a probody drug conjugate (PDC) targeting CD71 for the treatment of multiple cancers. Presented at American Association for Cancer Research Annual Meeting, New Orleans, Louisiana, April 16 - 20, 2016. http://cytomx.com/wp-content/uploads/2016/04/Preclinical-Development-of-a-ProbodyTM-Drug-Conjugate-PDC-Targeting-CD71-for-the-Treatment-of-Multiple-Cancers-AACR-2016.pdf
Weaver AY et al (2015) Development of a probody drug conjugate (PDC) targeting CD166 for the treatment of multiple cancers. Presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Boston, Massachusetts, November 5 - 9, 2015 http://cytomx.com/wp-content/uploads/2015/11/20151104_CD166_AACR_NCI_EORTC_poster_TO_PRINT_FINAL.pdf
Takebe N et al (2014) Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther 141:140–149
Wei P et al (2010) Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther 9(6):1618–1628
Dumortier A et al (2010) Atopic dermatitis-like disease and associated lethal myeloproliferative disorder arise from loss of notch signaling in the murine skin. PLoS One 5(2):e9258
Sagert J et al (2013) Tumor-specific inhibition of Jagged-dependent notch signaling using a Probody™ Therapeutic. Presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, October 19-23, 2013. Mol Cancer Ther 2013;12(11 Suppl):C158
Sagert J et al (2014) Transforming Notch ligands into tumor-antigen targets: a probody-drug conjugate (PDC) targeting Jagged 1 and Jagged 2. Presented at AACR Annual Meeting, San Diego, CA April 5-9, 2014. Cancer Res 2014;74(19 Suppl):Abstract 2665
Weidle UH et al (2010) ALCAM/CD166: cancer-related issues. Cancer Genomics Proteomics 7(5):231–243
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Lin, J., Sagert, J. (2018). Targeting Drug Conjugates to the Tumor Microenvironment: Probody Drug Conjugates. In: Damelin, M. (eds) Innovations for Next-Generation Antibody-Drug Conjugates. Cancer Drug Discovery and Development. Humana Press, Cham. https://doi.org/10.1007/978-3-319-78154-9_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-78154-9_12
Published:
Publisher Name: Humana Press, Cham
Print ISBN: 978-3-319-78153-2
Online ISBN: 978-3-319-78154-9
eBook Packages: MedicineMedicine (R0)